FORT LAUDERDALE, Fla., July 17, 2012 (GLOBE NEWSWIRE) -- OmniComm
Systems, Inc. (OTCBB:OMCM) announced the immediate availability of
TrialMaster version 4.1.2, its flagship product for Electronic Data
Capture (EDC). This latest version of TrialMaster introduces Dynamic
Monitoring, a feature that allows organizations conducting clinical
trials to significantly reduce their monitoring costs, while showing
compliance with the FDA's new draft guidance on risk-based monitoring.
This feature allows customers to control how much of the data in a
given trial needs to be verified against source documents, such as
specifying that half the patients should have full monitoring and half
should be monitored for critical variables only. The specification can
vary by investigative site, allowing the sponsor or Contract Research
Organization (CRO) to focus its monitoring resources to maximize
effectiveness.

This new release also features a variety of significant functionality
enhancements including: major improvements to the management of
laboratory reference ranges, an upgrade to LogiXML(TM) version 10 for
ad-hoc reporting, the ability to control security at the item level,
and a new capability to attach images and other types of files to
electronic Case Report Forms. These attached files are also included in
the PDFs of patient data that are produced at the end of the study,
allowing FDA reviewers to see images and scanned documents alongside
the submitted textual data.

"TrialMaster already offers the industry's most intuitive EDC product,
providing sites an unequalled level of interactivity," said Keith
Howells, SVP of Development at OmniComm. "This new release provides
tremendous additional benefits to the sponsor companies, notably
allowing them to implement risk-based monitoring plans and thus drive
down costs without impacting quality. We are looking forward to a
speedy adoption of these new capabilities."

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven
Internet solutions to pharmaceutical, biotechnology, research and
medical device organizations that conduct life changing clinical trial
research. OmniComm's growing base of satisfied customers is a direct
result of the company's commitment to deliver products and services
that ensure ease of use, faster study build, ease of integration and
better performance. OmniComm Systems, Inc. has U.S. headquarters in
Fort Lauderdale, FL and European headquarters in Bonn, Germany, with
satellite offices in New Jersey and the United Kingdom, as well as
sales offices throughout the U.S. and Europe.

The OmniComm Systems Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13414

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of
risks and uncertainties such as the Company's ability to obtain new
contracts and accurately estimate net revenues due to uncertain
regulatory guidance, variability in size, scope and duration of
projects, and internal issues at the sponsoring client, integration of
acquisitions, competitive factors, technological development, and
market demand. As a result, actual results may differ materially from
any financial outlooks stated herein. Further information on potential
factors that could affect the Company's financial results can be found
in the Company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. The Company undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events, or otherwise.


CONTACT: Bev Hudson
         OmniComm Systems, Inc.
         954-473-1254
         bhudson@omnicomm.com